134 related articles for article (PubMed ID: 25670033)
1. A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer.
Stegeman S; Moya L; Selth LA; Spurdle AB; Clements JA; Batra J
Endocr Relat Cancer; 2015 Apr; 22(2):265-76. PubMed ID: 25670033
[TBL] [Abstract][Full Text] [Related]
2. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
[TBL] [Abstract][Full Text] [Related]
3. A Regulatory MDM4 Genetic Variant Locating in the Binding Sequence of Multiple MicroRNAs Contributes to Susceptibility of Small Cell Lung Cancer.
Gao F; Xiong X; Pan W; Yang X; Zhou C; Yuan Q; Zhou L; Yang M
PLoS One; 2015; 10(8):e0135647. PubMed ID: 26274820
[TBL] [Abstract][Full Text] [Related]
4. The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.
Gansmo LB; Bjørnslett M; Halle MK; Salvesen HB; Dørum A; Birkeland E; Hveem K; Romundstad P; Vatten L; Lønning PE; Knappskog S
Tumour Biol; 2016 Aug; 37(8):10697-702. PubMed ID: 26867771
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the Association between MDM4 rs4245739 Single Nucleotide Polymorphism and Breast Cancer Susceptibility.
Pedram N; Pouladi N; Feizi MA; Montazeri V; Sakhinia E; Estiar MA
Clin Lab; 2016 Jul; 62(7):1303-1308. PubMed ID: 28164646
[TBL] [Abstract][Full Text] [Related]
6. Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma.
Zhou L; Zhang X; Li Z; Zhou C; Li M; Tang X; Lu C; Li H; Yuan Q; Yang M
PLoS One; 2013; 8(5):e64331. PubMed ID: 23724042
[TBL] [Abstract][Full Text] [Related]
7. MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk.
Gansmo LB; Romundstad P; Birkeland E; Hveem K; Vatten L; Knappskog S; Lønning PE
Cancer Med; 2015 Dec; 4(12):1901-7. PubMed ID: 26471763
[TBL] [Abstract][Full Text] [Related]
8. MDM4 rs4245739 A > C polymorphism correlates with reduced overall cancer risk in a meta-analysis of 69477 subjects.
Xu C; Zhu J; Fu W; Liang Z; Song S; Zhao Y; Lyu L; Zhang A; He J; Duan P
Oncotarget; 2016 Nov; 7(44):71718-71726. PubMed ID: 27687591
[TBL] [Abstract][Full Text] [Related]
9. A genetic variant within MDM4 3'UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer.
Zhang Y; Sturgis EM; Wei P; Liu H; Wang Z; Ma Y; Liu C; Gu KJ; Wei Q; Li G
Mol Carcinog; 2019 Dec; 58(12):2276-2285. PubMed ID: 31513313
[TBL] [Abstract][Full Text] [Related]
10. Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility.
Liu J; Tang X; Li M; Lu C; Shi J; Zhou L; Yuan Q; Yang M
Breast Cancer Res Treat; 2013 Jul; 140(1):151-7. PubMed ID: 23793604
[TBL] [Abstract][Full Text] [Related]
11. Profile of the breast cancer susceptibility marker rs4245739 identifies a role for miRNAs.
Anwar SL; Wulaningsih W; Watkins J
Cancer Biol Med; 2017 Nov; 14(4):387-395. PubMed ID: 29372105
[TBL] [Abstract][Full Text] [Related]
12. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer.
Shen PF; Chen XQ; Liao YC; Chen N; Zhou Q; Wei Q; Li X; Wang J; Zeng H
Prostate; 2014 May; 74(7):756-67. PubMed ID: 24644030
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame.
Mandke P; Wyatt N; Fraser J; Bates B; Berberich SJ; Markey MP
PLoS One; 2012; 7(8):e42034. PubMed ID: 22870278
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
16. The associations between MDM4 gene polymorphisms and cancer risk.
Wang MJ; Luo YJ; Shi ZY; Xu XL; Yao GL; Liu RP; Zhao H
Oncotarget; 2016 Aug; 7(34):55611-55623. PubMed ID: 27742919
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer.
Fuse M; Kojima S; Enokida H; Chiyomaru T; Yoshino H; Nohata N; Kinoshita T; Sakamoto S; Naya Y; Nakagawa M; Ichikawa T; Seki N
J Hum Genet; 2012 Nov; 57(11):691-9. PubMed ID: 22854542
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer.
Verdoodt B; Neid M; Vogt M; Kuhn V; Liffers ST; Palisaar RJ; Noldus J; Tannapfel A; Mirmohammadsadegh A
Int J Oncol; 2013 Jul; 43(1):307-14. PubMed ID: 23612742
[TBL] [Abstract][Full Text] [Related]
19. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Corcoran C; Rani S; O'Driscoll L
Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
[TBL] [Abstract][Full Text] [Related]
20. Lack of Associations of the MDM4 rs4245739 Polymorphism with Risk of Thyroid Cancer among Iranian-Azeri Patients: a Case-Control Study.
Mohammad Khanlou Z; Pouladi N; Hosseinpour Feizi M; Pedram N
Asian Pac J Cancer Prev; 2017 Apr; 18(4):1133-1138. PubMed ID: 28547953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
